# A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

> **NCT04294160** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 122 (actual)

## Conditions studied

- BRAF V600 Colorectal Cancer

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** LTT462
- **DRUG:** Trametinib
- **DRUG:** LXH254
- **DRUG:** TNO155
- **BIOLOGICAL:** Spartalizumab
- **BIOLOGICAL:** Tislelizumab

## Key facts

- **NCT ID:** NCT04294160
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-22
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 122 (ACTUAL)
- **Why stopped:** The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04294160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04294160, "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04294160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*